Table 1. Patient characteristics.
| Patient cohort | n = 278 | ||
| Age mean (range) | 43.5 (2–72) | ||
| Gender | n | ||
| Female | 119 | ||
| Male | 159 | ||
| Diagnosis | n | ||
| ALL | 41 | ||
| AML | 104 | ||
| sAML | 29 | ||
| CLL | 5 | ||
| CML | 9 | ||
| MDS | 35 | ||
| solid tumors/lymphoma | 31 | ||
| other diseases with indication for HSCT | 24 | ||
| CMV reactivations/CMV DeNovo Infection in the various | |||
| CMV-serostatus recipient (R)/donor (D) group | n/n | ||
| All patients | 117/278 | ||
| R+/D+ | 77/139 | ||
| R+/D− | 30/51 | ||
| R−/D+ | 7/39 | ||
| R−/D− | 3/49 | ||
| Donor | n | ||
| MRD | 87 | ||
| MUD | 131 | ||
| MMUD | 40 | ||
| MMRD | 20 | ||
| Transplant | n | ||
| BM | 35 | ||
| CD34 *106/kgBW (mean): | 3.1 | ||
| CD3 *106/kgBW (mean): | 25.8 | ||
| PBSC without TCD | 220 | ||
| CD34 *106/kgBW (mean): | 13.4 | ||
| CD3 *106/kgBW (mean): | 391.6 | ||
| PBSC with TCD | 21 | ||
| CD34 *106/kgBW (mean): | 10.4 | ||
| CD3 *106/kgBW (mean): | 0.03 | ||
| other* | 2 | ||
| Matched tetramers per patient | n | ||
| 1 tetramer | 102 | ||
| 2 tetramers | 126 | ||
| 3 tetramers | 49 | ||
| 4 tetramers | 1 | ||
| CMV-epitopes | n | ||
| HLA-A*0101 (pp50) | 95 | ||
| HLA-A*0201 (pp65) | 156 | ||
| HLA-A*1101 (pp65) | 1 | ||
| HLA-A*2402 (pp65) | 53 | ||
| HLA-B*0702 (pp65) | 73 | ||
| HLA-B*0801 (IE-1) | 77 | ||
| HLA-B*3501 (pp65) | 41 | ||
ALL: acute lymphatic leukemia; AML: acute myeloid leukemia; sAML: secondary AML; CLL; chronic lymphoid leukemia; CML: chronic myeloid leukemia; MDS: myelodysplastic syndrome;
MRD: matched related donor; MUD: matched; MMUD: mismatched unrelated donor; MMRD: mismatched related donor; TCD: T cell depletion.
BM: bone marrow; PBSC: peripheral blood stem cell;
*
cord blood.